|
|
Post by mytakeonit on Jun 15, 2019 14:59:10 GMT -5
Touting VDEX's 20% drop out rate is crazy ... they only have 300 patients. Every doc that I've been to will prescribe something and I follow the directions and use it. If it doesn't work, we look for another answer. But, I don't leave the doc because it failed. So, VDEX's 20% rate for dropouts ... actually makes them a loser.
July 1st is the start of progress ... pay off Deerfield ... more progress with UTHR ... maybe I buy more shares? Ha!
But, that's mytakeonit
|
|
|
|
Post by mnkdfann on Jun 15, 2019 15:11:31 GMT -5
Touting VDEX's 20% drop out rate is crazy ... they only have 300 patients. Every doc that I've been to will prescribe something and I follow the directions and use it. If it doesn't work, we look for another answer. But, I don't leave the doc because it failed. So, VDEX's 20% rate for dropouts ... actually makes them a loser. July 1st is the start of progress ... pay off Deerfield ... more progress with UTHR ... maybe I buy more shares? Ha! But, that's mytakeonit So VDEX is (or so it seems to have been suggested) state of the art when it comes to use of Afrezza training and education, and the drop out rate is STILL 20%? Some of that could be insurance related, but I thought we'd been told before that VDEX pretty much solved that issue for its clients? |
|
|
|
Post by sportsrancho on Jun 15, 2019 15:43:41 GMT -5
Simple question. If they have funding why are there no details in the so called proposal? Would you mind putting that in the question section on the other thread also. |
|
|
|
Post by sportsrancho on Jun 15, 2019 15:46:23 GMT -5
Over 80% retention does not mean they have a drop out rate of 20% they’re being very modest:-)
|
|
|
|
Post by celo on Jun 15, 2019 16:38:32 GMT -5
VDEX needs funding. For clinics to sprout up all over the place in these non-utilized states is going to take a lot of cash. 300 patients, if that truly is the amount VDEX has is equal to the same patient pool of 1 maybe 2 large endo practice(s).
MNKD truly needs a big Pharma partner that is loosing market share to alternative diabetic medications. Now that Mannkind has the necessary protocols (as proven in their studies) for patients to have success, they can partner with a company that is motivated to have the market share that Afrezza deserves. The beauty with one of the big Pharma is they have connections to every endo out there, allowing their reps to persuade doctors and patients. They probably have more sway with the FDA and ADA. I believe the initial Sanofi partnership was doomed from the beginning for multiple reasons. Mannkind is not there anymore and neither would be a future partner.
|
|
|
|
Post by sportsrancho on Jun 15, 2019 16:46:25 GMT -5
VDEX needs funding. For clinics to sprout up all over the place in these non-utilized states is going to take a lot of cash. 300 patients, if that truly is the amount VDEX has is equal to the same patient pool of 1 maybe 2 large endo practice(s). MNKD truly needs a big Pharma partner that is loosing market share to alternative diabetic medications. Now that Mannkind has the necessary protocols (as proven in their studies) for patients to have success, they can partner with a company that is motivated to have the market share that Afrezza deserves. The beauty with one of the big Pharma is they have connections to every endo out there, allowing their reps to persuade doctors and patients. They probably have more sway with the FDA and ADA. I believe the initial Sanofi partnership was doomed from the beginning for multiple reasons. Mannkind is not there anymore and neither would be a future partner. Great post, good points. Just saying...Vdex has their funding now, they are ready to roll:-) but they need to have some protection that they won’t get copycatted. |
|
|
|
Post by uvula on Jun 15, 2019 16:58:05 GMT -5
VDEX needs funding. For clinics to sprout up all over the place in these non-utilized states is going to take a lot of cash. 300 patients, if that truly is the amount VDEX has is equal to the same patient pool of 1 maybe 2 large endo practice(s). MNKD truly needs a big Pharma partner that is loosing market share to alternative diabetic medications. Now that Mannkind has the necessary protocols (as proven in their studies) for patients to have success, they can partner with a company that is motivated to have the market share that Afrezza deserves. The beauty with one of the big Pharma is they have connections to every endo out there, allowing their reps to persuade doctors and patients. They probably have more sway with the FDA and ADA. I believe the initial Sanofi partnership was doomed from the beginning for multiple reasons. Mannkind is not there anymore and neither would be a future partner. Great post, good points. Just saying...Vdex has their funding now, they are ready to roll:-) but they need to have some protection that they won’t get copycatted. Sports, you keep saying they have funding. They never said they had funding, not even in their proposal. There is no way mnkd can take the proposal seriously without this. |
|
|
|
Post by robbmo on Jun 15, 2019 17:23:51 GMT -5
I suspect VDEX is looking to get funding for whatever its planning from Mannkind. I also suspect the reason why the "Mannkind 2.0" plan didn't come to fruition was because funding VDEX was going to be too expensive. No, they have their own funding. Who is doing the funding? Please give names/organizations. |
|
|
|
Post by rtmd on Jun 15, 2019 19:03:06 GMT -5
It seems to me that if this were a viable plan, some big pharma would have already pursued it. I mean, why isn't Lilly bypassing distributors and pharmacies by selling humalog directly to consumers via specialty diabetes clinics? It would put that much more money in their pockets plus give them additional cash flow from whatever other services the clinics could offer.
|
|
|
|
Post by nylefty on Jun 15, 2019 19:54:00 GMT -5
It seems to me that if this were a viable plan, some big pharma would have already pursued it. I mean, why isn't Lilly bypassing distributors and pharmacies by selling humalog directly to consumers via specialty diabetes clinic? It would put that much more money in their pockets plus give them additional cash flow from whatever other services the clinics could offer.As I pointed out in a previous post, many states don't allow clinics or other medical practices to sell prescription drugs directly to consumers -- or only allow them to dispense a few days supply until their patients can get their prescriptions filled at a pharmacy. The closest that drug companies are getting to selling drugs directly to patients is by making arrangements with online pharmacies -- arrangements like the one MannKind has with Eagle or Pfizer has with CVS to sell Viagra online. |
|
|
|
Post by Thundersnow on Jun 15, 2019 20:33:41 GMT -5
VDEX needs funding. For clinics to sprout up all over the place in these non-utilized states is going to take a lot of cash. 300 patients, if that truly is the amount VDEX has is equal to the same patient pool of 1 maybe 2 large endo practice(s). MNKD truly needs a big Pharma partner that is loosing market share to alternative diabetic medications. Now that Mannkind has the necessary protocols (as proven in their studies) for patients to have success, they can partner with a company that is motivated to have the market share that Afrezza deserves. The beauty with one of the big Pharma is they have connections to every endo out there, allowing their reps to persuade doctors and patients. They probably have more sway with the FDA and ADA. I believe the initial Sanofi partnership was doomed from the beginning for multiple reasons. Mannkind is not there anymore and neither would be a future partner. Great post, good points. Just saying...Vdex has their funding now, they are ready to roll:-) but they need to have some protection that they won’t get copycatted. Not sure how they can prevent someone coming in and duplicating their business plan. Look what Google did to YAHOO. Having a distribution agreement will not prevent a competitor. MNKD will sign up the competitor too and I'm sure you're not thinking MNKD will make it exclusive? |
|
|
|
Post by agedhippie on Jun 15, 2019 21:04:04 GMT -5
Great post, good points. Just saying...Vdex has their funding now, they are ready to roll:-) but they need to have some protection that they won’t get copycatted. I am in favor of the deal since as far as I can see it is just giving VDEX the ability to buy direct provided they commit to certain quarterly minimum spend. I do not have a problem with barring other competitors (they are not asking for distributors to be barred) since I seriously doubt any clinic competitor would want to do this because of the distribution overhead. I am very skeptical that this is going to work to VDEX's advantage when they try and scale logistics as they build out clinics (aside from the legalities nylefty raises). The bigger problem though is going to be as insurance cover (slowly) improves - most insurers require you to use their mail order pharmacy for insulin if you want cover. That will remove that revenue stream from VDEX. As for copycatting; the clinics have a very low barrier to entry. For example CVS is already offering some diabetes service out of the minuteclinics in their pharmacies. If VDEX is a success it would not be hard for CVS to replicate the protocol from STAT and FB data, and even from VDEX's own papers. CVS could undercut VDEX for an inferior, but good enough, service (actually VDEX would be advised to see if they can do a deal with CVS over those clinics). |
|
|
|
Post by sportsrancho on Jun 15, 2019 21:09:28 GMT -5
Very good food for thought aged. Thank you.
|
|
|
|
Post by mnholdem on Jun 15, 2019 21:24:41 GMT -5
VDex’s treatment protocol is proprietary but that not what VDex would be seeking. The exclusivity agreement would be intended to block any competition from being able to purchase Afrezza directly from MannKind in the “abandoned states”. Any competing clinic, such as CVS, would need to purchase Afrezza from a distributor or send their patients to a pharmacy. I am assuming that VDex would be supplied with Afrezza at a minimum price.
|
|
|
|
Post by falconquest on Jun 15, 2019 21:27:40 GMT -5
VDex’s treatment protocol is proprietary but that not what VDex would be seeking. The exclusivity agreement would be intended to block any competition from being able to purchase Afrezza directly from MannKind in the “abandoned states”. Any competing clinic, such as CVS, would need to purchase Afrezza from a distributor or send their patients to a pharmacy. I am assuming that VDex would be supplied with Afrezza at a minimum price. Right. VDEX wants a level playing field from which to operate, can't blame them for that. |
|
